ESPERITE N.V. (ESP) WITH CRYOSAVE READY TO STORE MORE THAN A MILLION SAMPLES IN ITS NEW DESIGNED CRYOSTORAGE FACILITY IN GENEVA.

September 13, 2018 Group News

CryoSave has fully equipped this new safe and secure sample storage BioBank in its state-of-the-art central laboratory in Geneva, Switzerland especially designed for optimal cryopreservation of all biological samples and therefore provide peace of mind to institutional clients and families.

Amsterdam, The Netherlands – 13 September 2018
read more

ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).

July 2, 2018 Group News

ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).

CryoSave in its joint venture with Ecsponent (ECS) at equal participation have sold 100% of their stake for ZAR 50,000,000 (Fifty Million South African Rand).

As a leading stem cells bank, CryoSave SA will continue to as-sist Go Life Healthcare with its long-established professionalism and expertise.

Amsterdam, The Netherlands – 02 July 2018
read more

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

May 17, 2018 Group News

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

Amsterdam, The Netherlands – 17 May 2018

read more

Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases

March 29, 2018 Group News

Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.

Amsterdam, the Netherlands – 29 March 2018

read more

Page 1 of 1012345...10...Last »